Avaliação Bem-Estar Fetal Intra-Parto. Cardiotocografia e Electrocardiograma Fetal

A asfixia intra-parto é um evento raro, sendo o seu diagnóstico difícil. Pensa-se que a introdução e uso generalizado da cardiotocografia tenha permitido a identificação do feto em sofrimento, presumivelmente antes de ocorrer uma lesão permanente. O objectivo desta revisão é mostrar as bases da interpretação do CTG e as tentativas para uniformização de critérios na sua avaliação, bem como novas soluções para a descriminação dos “verdadeiros” casos de sofrimento fetal.

Bem Estar Fetal Intraparto: Papel da Ecografia

A realização de ecografia está disponível em praticamente todos os Serviços de Urgência de Ginecologia/Obstetrícia. A sua utilidade na avaliação do bem-estar fetal ante-parto é indiscutível. Este trabalho tem por objectivo rever as indicações da Ecografia realizada durante o Trabalho de Parto.

Morte Fetal Tardia - O Que Podemos Aprender?

Resumo: Realizou-se um estudo retrospectivo, comparativo sobre gestações com idade gestacional (IG) igual ou superior a 28 semanas, cujo parto resultou no nascimento de nado morto (n= 111) ou de nado-vivo (n= 16863), entre 2000 a 2004, na Maternidade Dr. Alfredo da Costa. Resultados: Não houve diferenças estatisticamente significativas na comparação da idade materna (28,9 vs 29,3; p= 0,3) e etnia. O grupo de mulheres com idade> 35 anos foi inferior no grupo da mortalidade fetal (18% vs. 26%, p= NS). A grande multiparidade associou-se significativamente com morte fetal tardia (3,6 vs. 0,7; p<0,005). A análise dos factores etiológicos mostrou que na maioria destas situações se identificam causas placentares, maternas ou funiculares. A morte fetal inexplicada representa 36% dos casos. Conclusões: O estudo da fetomortalidade é importante no esclarecimento dos pais e permite identificar etiologias passíveis de prevenção. A morte fetal inexplicada constitui ainda uma parcela significativa na mortalidade perinatal. A Fetopatologia e o estudo anatomo-patológico da placenta constituem instrumentos fundamentais para a sua compreensão.

Renal Disease in Madeira Islands: Twenty-Seven Years' Experience of Native Kidney Biopsies

Introduction: Renal biopsy plays an essential role either in the diagnosis or in the prognosis of patients with renal disease. In order to assess its epidemiology and evolution in Madeira Islands, we analysed twenty-seven years of native kidney biopsies. Methods: We performed a retrospective analysis of clinical records, including histological revision from 1986 to 2012, totalling 315 native kidney biopsies. They were assessed regarding the temporal evolution both for the quality/indications for renal biopsy and for the patterns of kidney disease. Results: A total of 315 native kidney biopsies were analysed. The patients’ mean age was of 40.8 ± 18.4 years and 50.5%(n = 159) were males. The most common indications for renal biopsy were nephrotic syndrome (36.2%, n = 114) and acute kidney injury (20.0%, n = 63). Among primary glomerular diseases (41.5%, n = 115) the most common were IgA nephropathy (26.1%, n = 30) and focal-segmental glomerulosclerosis (17.4%, n = 20) and among secondary glomerular diseases (31.4%, n = 87), lupus nephritis (51.7%, n = 45) and amyloidosis (20.7%, n = 18). Statistical analysis revealed significant correlation between gender and major pathological diagnosis (Fisher’s exact test, p <.01) and between indications for renal biopsy and major pathological diagnosis (χ2, p <.01). Regarding the temporal evolution, no statistically significant differences were found in the number of renal biopsies (χ2, p =.193), number of glomeruli per sample (Fisher’s exact test, p =.669), age (Kruskal-Wallis, p =.216), indications for renal biopsy (χ2, p =.106) or major pathological diagnosis groups (χ2,p =.649). However, considering the specific clinico-pathological diagnoses and their temporal variation, a statistically significant difference (Fisher’s exact test, p <.05) was found for lupus nephritis and membranous nephropathy with an increasing incidence and for amyloidosis with an opposite tendency. Discussion: The review of the native kidney biopsies from a population with particular characteristics, geographically isolated, such as those from Madeira Islands, showed parallel between epidemiological numbers referring to other European subpopulations, allowing simultaneously a comprehensive approach to our renal biopsy policies.

Morte Fetal de um Gémeo. Que Problemas para o Gémeo Sobrevivente?

Na gravidez bigemelar, a morte de um dos fetos no segundo e terceiro trimestre é uma complicação rara, variando a taxa de incidência entre 2,6 e 6,8%. Este acontecimento determina um aumento das taxas de morbilidade e mortalidade perinatal para o gémeo sobrevivente, especialmente em gravidezes monocoriónicas, quando a morte fetal é devida à síndroma de tranfusão feto-fetal. Para alguns autores o atraso de crescimento intrauterino e a prematuridade são os principais factores de risco para o aumento da morbilidade e mortalidade do gémeo sobrevivente. A patofisiologia de instalação dos distúrbios cerebrais no gémeo sobrevivente após a morte do feto irmão não está definida, nem o intervalo de tempo que medeia entre a morte e o estabelecimento das lesões. Também não existe um protocolo definitivo de seguimento destas gravidezes e, posteriormente, do gémeo sobrevivente. No período de 1 de Setembro de 1994 a 31 de Dezembro de 1998, foram seguidas, na consulta de Gravidez Múltipla da Maternidade Dr. Alfredo da Costa, 235 gravidezes bigemelares. Em nove casos (3,8%) ocorreu morte de um dos fetos com idade gestacional acima das 13 semanas. Em cinco das nove gravidezes foi conhecida a causa de morte, quatro das quais foram atribuídas à síndroma de tranfusão feto-fetal. A taxa de prematuridade do gémeo sobrevivente foi de 44,4% (4/9) e a de mortalidade de 11,1%(1/9). A taxa de morbilidade neonatal foi de 62,5% (5/8), na maioria dos casos por complicações inerentes à prematuridade. A taxa de morbilidade neurológica foi de 37,5% (3/8). A taxa de lesões neurológicas major foi de 25% (2/8) e ocorreu em recém-nascidos de termo. A síndroma de transfusão feto-fetal, como causa de morte fetal, associou-se aos casos com pior prognóstico no que se referiu ao gémeo sobrevivente.O crescimento do gémeo sobrevivente parece depender das lesões provocadas pela morte do feto irmão. Os autores finalizam com uma proposta de atitudes obstétricas e pediátricas em relação ao gémeo sobrevivente.

Disruption of Urate Transport in Familial Renal Glucosuria and Report on SGLT2 Expression in Normal and Pathological Kidney

Familial renal glucosuria (FRG) is a rare co -dominantly inherited benign phenotype characterized by the presence of glucose in the urine. It is caused by mutations in the SLC5A2 gene that encodes SGLT2, a Na+ -glucose co -transporter. The purpose of our current work was twofold: to characterize the molecular and phenotype findings of an FRG cohort and, in addition, to detail the SGLT2 expression in the adult human kidney. The phenotype of FRG pedigrees was evaluated using direct sequencing for the identification of sequence variations in the SLC5A2 gene. The expression of SGLT2 in the adult human kidney was studied by immunofluorescence on kidney biopsy specimens. In the absence of renal biopsies from FRG individuals, and in order to evaluate the potential disruption of SGLT2 expression in a glucosuric nephropathy, we have selected cases of nucleoside analogues induced proximal tubular toxicity. We identified six novel SLC5A2 mutations in six FRG pedigrees and described the occurrence of hyperuricosuria associated with hypouricaemia in the two probands with the most severe phenotypes. Histopathological studies proved that SGLT2 is localized to the brush -border of the proximal tubular epithelia cell and that this normal pattern was found to be disrupted in cases of nucleoside analogues induced tubulopathy. We present six novel SLC5A2 mutations, further contributing to the allelic heterogeneity in FRG, and identified hyperuricosuria and hypouricaemia as part of the FRG phenotype. SGLT2 is localized to the brush -border of the proximal tubule in the adult human normal kidney, and aberrant expression of the co -transporter may underlie the glucosuria seen with the use of nucleoside analogues.

Triple Regimen with Rituximab, Plasmapheresis and Intravenous Immunoglobulin in the Treatment of Dialysis Dependent Acute Humoral-Mediated Rejection in Kidney Grafts

Introduction: The clinical importance of humoral-mediated acute rejection has been progressively recognised. Early recognition and treatment with plasmapheresis and intravenous immunoglobulin have recently improved short term prognosis. Case report: In this report we describe the clinical features of three 2nd transplant patients developing severe acute humoral rejection during the first week post-transplant while on anti-thymocyte globulin therapy. Treatment with plasmapheresis/ intravenous immunoglobulin/rituximab resulted in rapid reversal of oliguria,and recovery of renal function within the 1st week of treatment in 2/3 patients. Diagnosis was confirmed by graft biopsies revealing peritubular neutrophiles and C4d deposits. Sequential graft biopsies in all three patients revealed complete histological recovery within two weeks. One patient never recovered renal function, and one patient lost his graft at three months following hemorrhagic shock. After 2 years follow up, the remaining patient maintains a serum creatinine of 1.1mg/dl. Conclusion: The regimen using plasmapheresis plus intravenous immunoglobulin and rituximab was effective in rapidly reversing severe acute humoral rejection.

Long-Term Survival (>25 Years) of Deceased Donor Kidney Transplant Recipients: a Single-Center Experience

INTRODUCTION: The aim of this preliminary work is to analyze the clinical features of 52 patients with a functional transplanted kidney for >25 years (all first transplant and all deceased donor recipients) and to compare with a similar though more complete study from Hôpital Necker-Paris 2012. METHODS: The mean graft survival at 25 years is 12.7% and at 30 years is 10%. The actual mean serum creatinine concentration is 1.3 mg/L. We analyzed recipient age (mean, 35.9 years) and gender (29 men and 23 women). Donor age was 26.7 ± 10.3 years. Seven patients (13.4%) were transplanted with 1 HLA mismatch, 42.3% with 2 mismatches, and 44.2% with 3 mismatches. Mean cold ischemia time was 15.45 ± 7.7 hours. Of the recipients, 76% had immediate graft function; 38% experienced 1 acute rejection episode and 4 patients had 2 rejection crises. The initial immunosuppressive regimen was azathioprine (AZA) + prednisolone (Pred) in 14 patients, cyclosporin (CSA) + Pred in 13 patients, and CSA + AZA + Pred in 25 patients. Of these patients, 19% maintained their initial regimen, and 54% (28 patients) were very stable on a mixed CSA regimen for >25 years. RESULTS: We present the major complications (diabetes, neoplasia, and hepatitis C virus positivity). CONCLUSION: Our results in deceased donor kidney recipients for >25 years are similar to the mixed population (deceased donors and living donors) presented by the Necker group, although 54% of our patients remain on CSA immunosuppression, contradicting the idea that its use is not compatible with good long-term kidney function in transplant recipients.

Acute Kidney Injury after Pediatric Cardiac Surgery: Risk Factors and Outcomes. Proposal for a Predictive Model

Objectives: To characterize the epidemiology and risk factors for acute kidney injury (AKI) after pediatric cardiac surgery in our center, to determine its association with poor short-term outcomes, and to develop a logistic regression model that will predict the risk of AKI for the study population. Methods: This single-center, retrospective study included consecutive pediatric patients with congenital heart disease who underwent cardiac surgery between January 2010 and December 2012. Exclusion criteria were a history of renal disease, dialysis or renal transplantation. Results: Of the 325 patients included, median age three years (1 day---18 years), AKI occurred in 40 (12.3%) on the first postoperative day. Overall mortality was 13 (4%), nine of whom were in the AKI group. AKI was significantly associated with length of intensive care unit stay, length of mechanical ventilation and in-hospital death (p<0.01). Patients’ age and postoperative serum creatinine, blood urea nitrogen and lactate levels were included in the logistic regression model as predictor variables. The model accurately predicted AKI in this population, with a maximum combined sensitivity of 82.1% and specificity of 75.4%. Conclusions: AKI is common and is associated with poor short-term outcomes in this setting. Younger age and higher postoperative serum creatinine, blood urea nitrogen and lactate levels were powerful predictors of renal injury in this population. The proposed model could be a useful tool for risk stratification of these patients.

Benefits of Selective Vitamin D Receptor Activators in Kidney Transplanted Patients

Severe chronic kidney disease may lead to disturbances, such as hyperphosphatemia, increased secretion of fibroblast growth factor -23 (FGF -23) and vitamin D deficiency. These may increase plasmatic levels of parathyroid hormone, and decrease plasmatic levels of calcium. Altogether, these may contribute to the development of secondary hyperparathyroidism, and to abnormalities in mineral metabolism. Kidney transplantation is the best option to improve longevity and quality of life in end -stage chronic kidney disease patients. Vitamin D deficiency has been associated with cardiovascular disease, which is the leading cause of death in chronic kidney disease. Therefore, diagnosing this deficiency may be pivotal for minimizing mortality in chronic kidney disease, because pharmacological treatments for this deficiency may be prescribed. Calcitriol is indicated for the treatment of vitamin D deficiency, both in chronic kidney disease and in kidney transplanted patients. However, calcitriol may increase the plasmatic levels of calcium and phosphorous, which can lead to vascular calcifications, that have been associated with cardiovascular mortality. Selective vitamin D receptor activators are indicated for the treatment of vitamin D deficiency in chronic kidney disease. These have the advantage of being associated with lower increases of plasmatic levels of calcium and phosphorous. These drugs also seem to have additional effects that may minimise patient morbidity and mortality, especially due to potentially reducing cardiovascular events. Unfortunately, there are few studies about the use of these drugs in kidney transplanted patients. Here we present a review about the physiology of vitamin D, the consequences of its deficiency in chronic kidney disease and in kidney transplanted patients, and about the diagnosis and treatment of this deficiency. Finally, we discuss the new line of research about the efficacy and safety of selective vitamin D receptor activators in kidney transplanted patients.